Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming scientific and medical conferences.

Event:	American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting (Baltimore, MD)
Date:	May 7–11, 2024
Format:	Oral Presentation/Abstract: Exosome-mediated intracellular delivery of arginase-1: a potential application for the treatment of Arginase-1 Deficiency
Event:	Parent Project Muscular Dystrophy (PPMD) Cardiac Workshop III (Baltimore, MD)
Date:	May 9–10, 2024
Format:	Panel: Industry perspectives on cardiac monitoring in DMD clinical trials
Event:	International Society of Extracellular Vesicles (ISEV) 2024 Meeting (Melbourne, Australia)
Date:	May 9–12, 2024
Format:	Abstract: Targeted cargo delivery to mouse lower limb by exosomes carrying a muscle targeting moiety with intravenous injection
Event:	CureDuchenne 2024 FUTURES National Conference (Orlando, FL)
Date:	May 23–26, 2024
Format:	Presentation: CAP-1002: an allogeneic cell therapy demonstrates disease modification in later-stage DMD patients: 24-month safety and efficacy results from the HOPE-2 open label extension
Event:	International Society for Cell & Gene Therapy (ISCT) 2024 Meeting (Vancouver, Canada)
Date:	May 29–June 1, 2024
Format:	Oral Presentation/Abstract: Targeted delivery of ASO using exosomes leads to mouse dystrophin exon skipping

The posters and/or abstracts will be made available on the publications section of the Capricor website following the conclusion of the meetings.